124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
11 clinical trials, 13 drugs (DrugBank: 4 drugs), 3 drug target genes, 11 drug target pathways
Searched query = "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy", "CADASIL", "Autosomal dominant cerebral artery disease with subcortical infarct and leukoencephalopathy", "Autosomal dominant cerebral artery disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04334408 (ClinicalTrials.gov) | January 2021 | 2/4/2020 | Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL | A Phase II Double-Blinded Placebo Controlled Individual Subject Stepped Wedge Clinical Trial Evaluating the Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL | Cadasil;Migraine | Drug: Fremanezumab;Drug: Placebo | Mayo Clinic | NULL | Not yet recruiting | 18 Years | 70 Years | All | 5 | Phase 2 | United States |